Clay Siegall’s newest inventions are gradually moving the world closer towards the realization of the cure for cancer. In a historic breakthrough in the field of cancer, the company developed and had its first drug ADCENTRIS (Brentuximab vedotin) approved by the United States Food and Drug Administration board for the treatment of Hodgkin Lymphoma as well as relapsed Hodgkin Lymphoma and relapse Large Cell Lymphoma. The drug use was approved by the European markets thus expanding its availability in more than 60 countries globally.
Welcoming the drug’s acceptance in the European Union markets, Seattle Genetics founder and CEO Clay Siegall said that his drug is the “first and only consolidation treatment available in both the United States and Europe for High-Risk classical lymphoma.” He also added that the drug’s potent is still not fully utilized and that his firm is working around the clock in experimenting its efficacy in treating over 70 forms of lymphomas. Most importantly, Siegall mentioned that his company is carrying out an innovative clinical research that seeks to use Adcetris as the sole treatment method for a newly detected Hodgkin Lymphoma which is currently considered incurable.
Clay Siegall’s other accomplishments
The fact that Adcentris is only FDA approved the drug for commercial use doesn’t mean it’s the only Seattle Genetics invention. The medical research and cancer treatment center is currently conducting final tests for 12 other drugs related to the treatment of different forms of cancer and cancer-related complications. Clay’s medical firm’s success in cancer research comes not only inspires hope to the global fight against the menace but also boosts the region dominance in cancer research. A fact that at one time attracted the visit of Vice President Joe Bidden to the region.
About Clay Siegall
Clay graduated with a Bachelors of Science in Zoology from Maryland University and later on acquired a Ph.D. in Genetics from the Universiy of George Washington. Nevertheless, He was introduced to cancer research while working with the National Cancer Institute as well as the Bristol-Meyers Squibb Pharmaceutical Research Institute. Having gained relevant experience in industry operations, Clay Siegall set out to establishing the now successful Seattle Genetics in 1998 where he serves as CEO, President, and Chairman of the Board of Advisers.